105 related articles for article (PubMed ID: 21321491)
1. Effects of 3-4 diaminopyridine (DAP) in motor neuron diseases.
Bertorini TE; Rashed H; Zeno M; Tolley EA; Igarashi M; Li YD
J Clin Neuromuscul Dis; 2011 Mar; 12(3):129-37. PubMed ID: 21321491
[TBL] [Abstract][Full Text] [Related]
2. 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.
Oh SJ; Claussen GG; Hatanaka Y; Morgan MB
Muscle Nerve; 2009 Nov; 40(5):795-800. PubMed ID: 19722254
[TBL] [Abstract][Full Text] [Related]
3. Treatment of the gravity dependence of downbeat nystagmus with 3,4-diaminopyridine.
Sprenger A; Rambold H; Sander T; Marti S; Weber K; Straumann D; Helmchen C
Neurology; 2006 Sep; 67(5):905-7. PubMed ID: 16966567
[TBL] [Abstract][Full Text] [Related]
4. Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine.
Mainero C; Inghilleri M; Pantano P; Conte A; Lenzi D; Frasca V; Bozzao L; Pozzilli C
Neurology; 2004 Jun; 62(11):2044-50. PubMed ID: 15184612
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus.
Kalla R; Spiegel R; Claassen J; Bardins S; Hahn A; Schneider E; Rettinger N; Glasauer S; Brandt T; Strupp M
J Neuroophthalmol; 2011 Dec; 31(4):320-5. PubMed ID: 21734596
[TBL] [Abstract][Full Text] [Related]
6. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
Quartel A; Turbeville S; Lounsbury D
Curr Med Res Opin; 2010 Jun; 26(6):1363-75. PubMed ID: 20377318
[TBL] [Abstract][Full Text] [Related]
7. No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study.
Lorenz D; Hagen K; Ufer M; Cascorbi I; Deuschl G; Volkmann J
Neurology; 2006 Jun; 66(11):1753-5. PubMed ID: 16769957
[TBL] [Abstract][Full Text] [Related]
8. A double-blind placebo-controlled study of 3,4-diaminopyridine in amytrophic lateral sclerosis patients on a rehabilitation unit.
Aisen ML; Sevilla D; Edelstein L; Blass J
J Neurol Sci; 1996 Jun; 138(1-2):93-6. PubMed ID: 8791245
[TBL] [Abstract][Full Text] [Related]
9. 3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study.
Flet L; Polard E; Guillard O; Leray E; Allain H; Javaudin L; Edan G
J Neurol; 2010 Jun; 257(6):937-46. PubMed ID: 20058019
[TBL] [Abstract][Full Text] [Related]
10. Inotropic effects of the K+ channel blocker 3,4-diaminopyridine on fatigued diaphragm muscle.
Ionno M; Moyer M; Pollarine J; van Lunteren E
Respir Physiol Neurobiol; 2008 Jan; 160(1):45-53. PubMed ID: 17881299
[TBL] [Abstract][Full Text] [Related]
11. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study.
Strupp M; Schüler O; Krafczyk S; Jahn K; Schautzer F; Büttner U; Brandt T
Neurology; 2003 Jul; 61(2):165-70. PubMed ID: 12874393
[TBL] [Abstract][Full Text] [Related]
12. Effect of 3,4-diaminopyridine on the postural control in patients with downbeat nystagmus.
Sprenger A; Zils E; Rambold H; Sander T; Helmchen C
Ann N Y Acad Sci; 2005 Apr; 1039():395-403. PubMed ID: 15826992
[TBL] [Abstract][Full Text] [Related]
13. The effect of 3,4-diaminopyridine on the patients with hereditary pure cerebellar ataxia.
Tsunemi T; Ishikawa K; Tsukui K; Sumi T; Kitamura K; Mizusawa H
J Neurol Sci; 2010 May; 292(1-2):81-4. PubMed ID: 20181362
[TBL] [Abstract][Full Text] [Related]
14. Long-lasting in vivo inotropic effects of the K(+) channel blocker 3,4-diaminopyridine during fatigue-inducing stimulation.
Van Lunteren E; Moyer M; Pollarine J
Muscle Nerve; 2008 Dec; 38(6):1616-22. PubMed ID: 19016549
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia.
Thakkar N; Guptill JT; Aleš K; Jacobus D; Jacobus L; Peloquin C; Cohen-Wolkowiez M; Gonzalez D;
CPT Pharmacometrics Syst Pharmacol; 2017 Sep; 6(9):625-634. PubMed ID: 28623849
[TBL] [Abstract][Full Text] [Related]
16. [Aminopyridines for symptomatic treatment of multiple sclerosis].
Jensen HB; Stenager E; Ravnborg MH
Ugeskr Laeger; 2011 Dec; 173(50):3259-63. PubMed ID: 22153210
[TBL] [Abstract][Full Text] [Related]
17. Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.
Oh SJ; Shcherbakova N; Kostera-Pruszczyk A; Alsharabati M; Dimachkie M; Blanco JM; Brannagan T; Lavrnić D; Shieh PB; Vial C; Meisel A; Komoly S; Schoser B; Sivakumar K; So Y;
Muscle Nerve; 2016 May; 53(5):717-25. PubMed ID: 26852139
[TBL] [Abstract][Full Text] [Related]
18. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment.
Judge SI; Bever CT
Pharmacol Ther; 2006 Jul; 111(1):224-59. PubMed ID: 16472864
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.
Wirtz PW; Verschuuren JJ; van Dijk JG; de Kam ML; Schoemaker RC; van Hasselt JG; Titulaer MJ; Tjaden UR; den Hartigh J; van Gerven JM
Clin Pharmacol Ther; 2009 Jul; 86(1):44-8. PubMed ID: 19357643
[TBL] [Abstract][Full Text] [Related]
20. Improvement of dy/dy dystrophic diaphragm by 3,4-diaminopyridine.
van Lunteren E; Moyer M
Muscle Nerve; 2002 Jul; 26(1):71-8. PubMed ID: 12115951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]